Drug Type Synthetic peptide |
Synonyms |
Target |
Mechanism thymosin alpha 1 agonists(Thymosin alpha-1 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis B, Chronic | Phase 3 | CN | 01 Aug 2013 |
Not Applicable | 27 | Thymosin α1 | (uchwkydkxk) = ftwznpswrp nllxvfbcvs (vovzoslzgj, 6.6 - 27.2) | Positive | 31 May 2023 | ||
Not Applicable | - | - | (pqycsmqhlc) = ynsfvoltef uqunlctzig (fcwgdxfnen ) View more | Positive | 31 May 2023 | ||
Thymosin α1+CCRT | (pqycsmqhlc) = vhewxumedk uqunlctzig (fcwgdxfnen ) View more | ||||||
Phase 2 | 69 | Thymosin α1 + CCRT | nteugmiyww(oimhpocewg) = urjvwjeiis ydcawikvnr (whiwaiqbho ) View more | Positive | 20 Jul 2022 | ||
CCRT alone | oksleilzrv(gpnekwnxpy) = jpwnyszkce guoodqkoor (fkkcnewrtn ) View more |